RxDoctor Payments Data

Kathya Jimenez

Nurse Practitioner · Tucson, AZNPI 1528754868

Payments from drug & device makers

$4,268in general payments, 2019–2025

Across 153 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$483
  • Daiichi Sankyo Inc.$460
  • Incyte Corporation$368
  • Merck$203
  • AstraZeneca$177
  • Sobi, Inc$163
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,83990%
  • Education$42910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,268 in reported general payments places this provider in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$85,974
Medicare patients
198
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate24$382,068
ImbruvicaIbrutinib22$345,392
VenclextaVenetoclax43$207,612
CalquenceAcalabrutinib Maleate12$129,902
NinlaroIxazomib Citrate12$120,814
NubeqaDarolutamide18$119,926
InlytaAxitinib18$81,900
CresembaIsavuconazonium Sulfate13$76,564
EliquisApixaban31$21,582
Imatinib Mesylate27$2,664
Hydroxyurea28$981
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$904
Prochlorperazine Maleate16$840
Morphine Sulfate13$670
Oxycodone Hcl20$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$368$382,06824 claims
AbbVieVenclexta$50$207,61243 claims
AstraZenecaCalquence$177$129,90212 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$111$120,81412 claims
BayerNubeqa$42$119,92618 claims
PfizerInlyta, Eliquis$143$103,48149 claims
Astellas Pharma US IncCresemba$17$76,56413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →